LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

0.95 1.06

Buy Sell

Overview

Share price change

24h

Current

Min

0.93

Max

Key metrics
By Trading Economics
Income	3.6M -34M
Sales	278K 1.9M
Profit margin	-1,786.576
Employees	181
EBITDA	979K -37M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+338.54% upside

Dividends
By Dow Jones
Next Earnings	10 lis 2025

Market Stats
By TradingEconomics
Market Cap	3.8M 111M
Previous open	-0.11
Previous close	0.95

News Sentiment

By Acuity

14%

86%

24 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 wrz 2025, 17:03 UTC

Major Market Movers

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 wrz 2025, 16:49 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

GD Culture Shares Drop After Deal for Pallas Capital

16 wrz 2025, 16:11 UTC

Major Market Movers

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 wrz 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16 wrz 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 wrz 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 wrz 2025, 21:10 UTC

Acquisitions, Mergers, Takeovers

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 wrz 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 wrz 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16 wrz 2025, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

16 wrz 2025, 20:25 UTC

Earnings

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 wrz 2025, 20:24 UTC

Earnings

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 wrz 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 wrz 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 wrz 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16 wrz 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 wrz 2025, 18:40 UTC

Acquisitions, Mergers, Takeovers

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 wrz 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 wrz 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 wrz 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 wrz 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 wrz 2025, 16:53 UTC

Earnings

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 wrz 2025, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

16 wrz 2025, 16:15 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Commodities Roundup: Market Talk

16 wrz 2025, 16:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Energy Roundup: Market Talk

16 wrz 2025, 16:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 wrz 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 wrz 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 wrz 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 wrz 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

338.54% upside

12 Months Forecast

Average 4.21 USD 338.54%

High 7 USD

Low 2 USD

Based on 9 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

24 / 371 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.